stockrowGilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.3%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
Follow GILD
Alert me
Gilead Sciences, Inc. (GILD) Revenue growth
Gilead Sciences, Inc.'s revenue growth over the twelve months to 30 September 2026 was 6.54%, up 4.1 percentage points from fiscal 2025 (2.40%). Over the past ten years it has ranged from −15.2% (fiscal 2018) to 31.1% (fiscal 2015); the current reading is higher than 64% of that period. That is in line with the Drug Manufacturers General industry median of 6.72% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 2.40% | (3.64) |
| FY2024 | 6.04% | 6.64 |
| FY2023 | −0.60% | (0.51) |
| FY2022 | −0.09% | (10.69) |
| FY2021 | 10.6% | 0.62 |
| FY2020 | 9.98% | 8.52 |
| FY2019 | 1.46% | 16.70 |
| FY2018 | −15.2% | (1.15) |
| FY2017 | −14.1% | (7.20) |
| FY2016 | −6.89% | (38.02) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 6.83% | (3.35) |
| Jun 2026 | 10.2% | 5.79 |
| Mar 2026 | 4.39% | (0.31) |
| Dec 2025 | 4.70% | 1.73 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SNY Sanofi compare | 26.3% |
| NVO Novo Nordisk A/S compare | 13.2% |
| AMGN Amgen Inc. compare | 8.15% |
| AZN AstraZeneca PLC compare | 7.32% |
| GILD Gilead Sciences, Inc. | 6.54% |
| MRK Merck & Co., Inc. compare | 4.89% |
| BMY Bristol Myers Squibb Company compare | 4.16% |
| NVS Novartis AG compare | 1.76% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement